| References: |
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants. TPX-0005 is a small molecule kinase inhibitor — for the treatment of non–small cell lung adenocarcinoma with an ALK, ROS1, or NTRK mutation.TPX-0005 demonstrates potent inhibitory effects against solvent mutations after multiple treatments, including ALK G1202R, ROS1 G2032R, TRKA G595R, and TRKC G623R.The FDA based its approval on the findings from the ongoing TRIDENT-1 trial (ClinicalTrial.gov Identifier: NCT03093116), a “phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics, and anti-tumor activity of TPX-0005 in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements. |
